KOREAN DRUG CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,190 KRW | -5.35% |
|
-5.93% | -13.79% |
| 2023 | Korean Drug Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| 2021 | Tranche Update on Korean Drug Co., Ltd.'s Equity Buyback Plan announced on December 14, 2020. | CI |
| Sales 2022 | 79.98B 58.63M | Sales 2023 | 81.37B 59.65M | Capitalization | 78.35B 57.43M |
|---|---|---|---|---|---|
| Net income 2022 | 11.81B 8.66M | Net income 2023 | -4.92B -3.6M | EV / Sales 2022 | 0.74 x |
| Net cash position 2022 | 26.34B 19.3M | Net cash position 2023 | 16.69B 12.23M | EV / Sales 2023 | 0.76 x |
| P/E ratio 2022 |
7.15
x | P/E ratio 2023 |
-15.7
x | Employees | 270 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 47.87% |
More Fundamentals
* Assessed data
More news
| 1 day | -5.35% | ||
| 1 week | -5.93% | ||
| Current month | -8.43% | ||
| 1 month | -8.43% | ||
| 3 months | -10.55% | ||
| 6 months | -9.10% | ||
| Current year | -13.79% |
1 week
6 160.00
6 700.00
1 month
6 160.006 930.00
Current year
6 160.007 980.00
1 year
5 870.007 980.00
3 years
5 870.0012 150.00
5 years
4 675.0015 800.00
10 years
3 705.0015 800.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sang-Hoon Park
CEO | Chief Executive Officer | 57 | - |
Hae-Ryong Park
CEO | Chief Executive Officer | 88 | - |
Kyung-Deuk Lee
BRD | Director/Board Member | 62 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hae-Ryong Park
CEO | Chief Executive Officer | 88 | - |
Sang-Hoon Park
CEO | Chief Executive Officer | 57 | - |
Kyung-Deuk Lee
BRD | Director/Board Member | 62 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 6,150 | -0.65% | 49,017 |
| 24-04-30 | 6,190 | -5.35% | 188,646 |
| 24-04-29 | 6,540 | -1.51% | 41,500 |
| 24-04-26 | 6,640 | -.--% | 11,996 |
| 24-04-25 | 6,640 | +0.76% | 13,327 |
End-of-day quote Korea S.E., April 29, 2024
More quotes
KOREAN DRUG CO.,LTD is a Korea-based company engaged in the manufacture and distribution of pharmaceuticals. The Companyâs products portfolio consists of over-the-counter (OTC) medicines, ethical (ETC) medicines and health food, including multi-symptom cold medicines, blood-forming nutrients, treatments for central nervous system, remedies for respiratory diseases, dermatological agents, vitamins, antifungal agents, antipyretics, analgesics, anti-inflammatory drugs, antibiotics, allergic treatments, calcium and vitamin D tablets and home pregnancy test kits, among others.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -13.79% | 48.81M | |
| +20.61% | 43.18B | |
| +20.67% | 22.59B | |
| +14.56% | 14.56B | |
| +13.94% | 13.54B | |
| +43.35% | 11.5B | |
| -8.37% | 6.93B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.21% | 5.36B |
- Stock Market
- Equities
- A014570 Stock
